welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
State-Of-The-Art Equipment In Place Thanks To FundraiserState-Of-The-Art Equipment In Place Than...
-
living with fap- familial adenomatous polyposisThis is a support group for people livin...
-
Efficacy and Safety of Eflornithine (CPP-1X)/Sulindac Combination Therapy Versus Each as Monotherapy in Patients wit...BACKGROUND: Molecular studies suggest i...
-
An International Randomised Trial of Celecoxib versus Celecoxib plus Difluoromethylornithine in Patients with Famili...BACKGROUND AND AIM : Although Non-steroi...
-
Low-Dose Dacarbazine-Doxorubicin Therapy Against Intra-Abdominal Desmoid TumorsIntra-abdominal desmoid tumor is a life-...
-
How to Take Charge of Your Medical RecordsPatients have a lot to gain by getting a...
-
Katherine Berry, MSKatherine Berry, MS, is a board certifie...